echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > A wholly-owned subsidiary of Kexing Pharmaceuticals cooperates with Antaiwei to develop small-molecule oral drugs against the new coronavirus

    A wholly-owned subsidiary of Kexing Pharmaceuticals cooperates with Antaiwei to develop small-molecule oral drugs against the new coronavirus

    • Last Update: 2022-03-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 20, Kexing Pharmaceutical announced that its wholly-owned subsidiary Shenzhen Kexing signed the "SHEN26 Project Cooperation Agreement" (hereinafter referred to as the "Cooperation Agreement") with Antaiwei on February 18.


    SHEN26 is an antiviral drug for the treatment of novel coronavirus and other viral infections.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.